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Background: There is a disproportionate burden of hypertension in African-Americans and less than 30% of African-Americans achieve blood 
pressure control with medications. Regulation of adipose tissue may represent an important link between increased insulin resistance, hypertension, 
and obesity, all key factors in the metabolic syndrome. Inflammation is involved in multiple stages of the development of atherosclerosis and serum 
levels of inflammatory markers including sVCAM-1 and sIL-6 may be used to predict cardiovascular disease risk. Nebivolol is a highly cardioselective 
vasodilatory beta1 receptor blocker that lowers blood pressure. We sought to determine whether nebivolol has beneficial effects on vascular markers 
of inflammation and oxidation in obese African-American patients with hypertension when exposed to exercise-induced stress. 
Methods: 43 obese, African-American subjects with hypertension were treated with nebivolol (5-10 mg/day) for 8 weeks. Prior to treatment, the 
subjects underwent an exercise treadmill study to a level of 8 metabolic equivalents. Circulating levels of sIL-6, VCAM-1, adiponectin, and leptin were 
measured at pre-treadmill, and 1 minute, 30 minutes, 60 minutes, and 24 hours after treadmill. After the 8 week treatment period, exercise treadmill 
study and the measurement of markers were repeated. 
Results: Treatment with nebivolol reduced levels of sVCAM-1 at pre-exercise by 21% and at 1 and 30 minutes by 12.5% and 20% respectively 
(p<0.005 from corresponding time point). In nebivolol treated patients there was a reduction in sIL-6 levels by 20% and pre-exercise and at 1 
and 60 minutes by 19.7% and 33.5%, respectively (p<0.005 from corresponding time point). Treatment with nebivolol increased levels of serum 
adiponectin by 28% (p=0.012) and decreased levels of leptin by 32% (p<0.005 from pre-treatment). 
Conclusions: Treatment with nebivolol improves markers of inflammation and obesity in a high-risk African-American population. Moreover, this 
effect is potentiated in response to exercise-induced stress. These results suggest that nebivolol differentially regulates markers of inflammation and 
obesity, thereby providing vascular protection.
